- Home
- IKT vs GHI Comparison
IKT vs GHI Comparison
Compare IKT & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IKT | GHI |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.3M | 161.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | IKT | GHI |
|---|---|---|
| Price | $1.69 | $7.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $6.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 704.4K | 208.2K |
| Earning Date | 11-14-2025 | 02-19-2026 |
| Dividend Yield | N/A | ★ 20.05% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.17 |
| Revenue | N/A | ★ $26,247,399.00 |
| Revenue This Year | N/A | $201.02 |
| Revenue Next Year | N/A | $2.87 |
| P/E Ratio | ★ N/A | $43.75 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.33 | $6.01 |
| 52 Week High | $3.32 | $13.29 |
Technical Indicators
Market Signals| Indicator | IKT | GHI |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 62.88 |
| Support Level | $1.63 | $7.28 |
| Resistance Level | $1.73 | $7.75 |
| Average True Range (ATR) | 0.19 | 0.36 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 17.29 | 98.18 |
Price Performance
Historical ComparisonAbout IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.